Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

NCT02926196 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

474

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Neoplasms

Interventions

DRUG: MSB0010718C

Sponsor

Istituto Oncologico Veneto IRCCS

Collaborators

[object Object]
[object Object]